AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
April 17 2007 - 8:30AM
PR Newswire (US)
JMR-132 could provide a new therapeutic approach for the treatment
of early and metastatic breast cancer QUEBEC CITY, April 17
/PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq:
AEZS), a global, pure play biopharmaceutical company focused on
endocrine therapy and oncology, today presented an abstract
outlining in vivo data for its growth hormone-releasing hormone
(GHRH) antagonist JMR-132 in breast cancer, at the American
Association for Cancer Research (AACR) Annual Meeting being held
this week at the Los Angeles Convention Center in Los Angeles,
California. Results The poster #3568 "GHRH-Antagonist in
Combination with Docetaxel Chemotherapy induces regression of MX-1
human experimental breast cancers," reviewed preclinical results in
breast cancer for JMR-132, the Company's GHRH antagonist which
binds to splice variants of the GHRH receptors found on various
cancerous tumors. More specifically, the authors reported on the
antitumor activity of JMR-132 in MX-1 human experimental,
doxorubicin-resistant breast cancers, as well as on the
anti-proliferative effect of JMR-132 in combination with docetaxel,
which is frequently used for the treatment of early and metastatic
breast cancer. Binding sites were found for GHRH in the MX-1 human
breast cancer cell line. The treatment of nude mice bearing MX-1
xenografts with JMR-132 at the dose of 10 (micro)g/day s.c.
significantly (p